Treatment options for transformed lymphoma: Incorporating allogeneic stem cell transplantation in a multimodality approach

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 9, 2011, Pages 1265-1272

  Reddy, Nishitha ^a   Savani, Bipin N ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Allogeneic stem cell transplant; Autologous stem cell transplant; Radioimmunotherapy; Transformed lymphoma

Indexed keywords

BENDAMUSTINE; IBRITUMOMAB TIUXETAN; RITUXIMAB; TOSITUMOMAB I 131;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; EXTERNAL BEAM RADIOTHERAPY; FOLLICULAR LYMPHOMA; HUMAN; LONG TERM CARE; NONHODGKIN LYMPHOMA; PROGNOSIS; REVIEW; SURVIVAL TIME; TRANSFORMED NONHODGKIN LYMPHOMA; TREATMENT OUTCOME;

DISEASE MANAGEMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 80051672479     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.05.002     Document Type: Review

References (65)

1. Bernstein S.H., Burack W.R. The incidence, natural history, biology, and treatment of transformed lymphomas. Hematology Am Soc Hematol Educ Program 2009, 532-541.
2. Gine E., Montoto S., Bosch F., et al. The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol 2006, 17:1539-1545.
3. Al-Tourah A.J., Gill K.K., Chhanabhai M., et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:5165-5169.
4. Bastion Y., Sebban C., Berger F., et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 1997, 15:1587-1594.
5. Garvin A.J., Simon R.M., Osborne C.K., et al. An autopsy study of histologic progression in non-Hodgkin's lymphomas. 192 cases from the National Cancer Institute. Cancer 1983, 52:393-398.
6. Ahmed S., Winter J.N., Gordon L.I., Evens A.M. Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications. Leuk Lymphoma 2010, 51:1163-1177.
7. Oliansky D.M., Gordon L.I., King J., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. Biol Blood Marrow Transplant 2010, 16:443-468.
8. Davies A.J., Rosenwald A., Wright G., et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol 2007, 136:286-293.
9. Carlotti E., Wrench D., Matthews J., et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone. Blood 2009, 113:3553-3557.
10. Rossi D., Berra E., Cerri M., et al. Aberrant somatic hypermutation in transformation of follicular lymphoma and chronic lymphocytic leukemia to diffuse large B-cell lymphoma. Haematologica 2006, 91:1405-1409.
11. Lawrie C.H., Chi J., Taylor S., et al. Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med 2009, 13:1248-1260.
12. Martinez-Climent J.A., Alizadeh A.A., Segraves R., et al. Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood 2003, 101:3109-3117.
13. Glas A.M., Knoops L., Delahaye L., et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 2007, 25:390-398.
14. Farinha P., Al-Tourah A., Gill K., et al. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood 2010, 115:289-295.
15. Carreras J., Lopez-Guillermo A., Fox B.C., et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006, 108:2957-2964.
16. Carreras J., Lopez-Guillermo A., Roncador G., et al. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol 2009, 27:1470-1476.
17. Ghesquieres H., Berger F., Felman P., et al. Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis. J Clin Oncol 2006, 24:5234-5241.
18. Friedberg J.W., Freedman A.S. High-dose therapy and stem cell transplantation in follicular lymphoma. Ann Hematol 1999, 78:203-211.
19. Barosi G., Carella A., Lazzarino M., et al. Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. Haematologica 2005, 90:1236-1257.
20. Al-Tourah A.J., Savage K.J., Gill K.K., et al. Addition of rituximab to CHOP chemotherapy significantly improves survival of patients with transformed lymphoma. ASH Annu Meet Abstr 2007, 110:790.
21. Friedberg J.W., Cohen P., Chen L., et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008, 26:204-210.
22. Noy A., Schoder H., Gonen M., et al. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Ann Oncol 2009, 20:508-512.
23. Yuen A.R., Kamel O.W., Halpern J., Horning S.J. Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol 1995, 13:1726-1733.
24. Buchsbaum D.J., Wahl R.L., Normolle D.P., Kaminski M.S. Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res 1992, 52:6476-6481.
25. Golay J., Zaffaroni L., Vaccari T., et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000, 95:3900-3908.
26. Witzig T.E., Flinn I.W., Gordon L.I., et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002, 20:3262-3269.
27. Davies A.J., Rohatiner A.Z., Howell S., et al. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2004, 22:1469-1479.
28. Kaminski M.S., Zelenetz A.D., Press O.W., et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001, 19:3918-3928.
29. Vose J.M., Wahl R.L., Saleh M., et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2000, 18:1316-1323.
30. Horning S.J., Younes A., Jain V., et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005, 23:712-719.
31. Kaminski M.S., Estes J., Zasadny K.R., et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000, 96:1259-1266.
32. Fisher R.I., Kaminski M.S., Wahl R.L., et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005, 23:7565-7573.
33. Fietz T., Uharek L., Gentilini C., et al. Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan. Leuk Lymphoma 2006, 47:59-63.
34. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995, 333:1540-1545.
35. Laudi N., Arora M., Burns L.J., et al. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005, 11:129-135.
36. Laport G.G. The role of hematopoietic cell transplantation for follicular non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006, 12:59-65.
37. Chen C.I., Crump M., Tsang R., Stewart A.K., Keating A. Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma. Br J Haematol 2001, 113:202-208.
38. Sabloff M., Atkins H.L., Bence-Bruckler I., et al. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Biol Blood Marrow Transplant 2007, 13:956-964.
39. Smith S.D., Bolwell B.J., Advani A.S., et al. High rate of survival in transformed lymphoma after autologous stem cell transplant: pathologic analysis and comparison with de novo diffuse large B-cell lymphoma. Leuk Lymphoma 2009, 50:1625-1631.
40. Kasamon Y.L., Jones R.J., Gocke C.D., et al. Extended follow-up of autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide (4-HC) purging for indolent or transformed non-Hodgkin lymphomas. Biol Blood Marrow Transplant 2011, 17:365-373.
41. Andreadis C., Schuster S.J., Chong E.A., et al. Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma. Bone Marrow Transplant 2005, 36:955-961.
42. Hamadani M., Benson D.M., Lin T.S., et al. High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. Eur J Haematol 2008, 81:425-431.
43. Foran J.M., Apostolidis J., Papamichael D., et al. High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre. Ann Oncol 1998, 9:865-869.
44. Williams C.D., Harrison C.N., Lister T.A., et al. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol 2001, 19:727-735.
45. Schouten H.C., Bierman P.J., Vaughan W.P., et al. Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation. Blood 1989, 74:2579-2584.
46. Dilhuydy M.S., Lamy T., Foussard C., et al. Front-line high-dose chemotherapy with rituximab showed excellent long-term survival in adults with aggressive large B-cell lymphoma: final results of a Phase II GOELAMS Study. Biol Blood Marrow Transplant 2010, 16:672-677.
47. Barrett A.J., Savani B.N. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 2006, 20:1661-1672.
48. Shea T., Johnson J., Westervelt P., et al. Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901. Biol Blood Marrow Transplant 2011.
49. Doocey R.T., Toze C.L., Connors J.M., et al. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 2005, 131:223-230.
50. Rezvani A.R., Storer B., Maris M., et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:211-217.
51. Clavert A., Le G.S., Brissot E., et al. Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma 2010, 51:1502-1508.
52. Thomson K.J., Morris E.C., Bloor A., et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009, 27:426-432.
53. Hamadani M., Benson D.M., Hofmeister C.C., et al. Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-Hodgkin lymphomas. Biol Blood Marrow Transplant 2009, 15:547-553.
54. Ramadan K.M., Connors J.M., Al-Tourah A.J., et al. Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results. Bone Marrow Transplant 2008, 42:601-608.
55. Hamadani M., Awan F.T., Elder P., et al. Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. Leuk Lymphoma 2008, 49:1893-1898.
56. Khouri I.F., McLaughlin P., Saliba R.M., et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008, 111:5530-5536.
57. Reddy N., Rezvani K., Barrett A.J., Savani B.N. Strategies to prevent EBV reactivation and post-transplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high risk patients. Biol Blood Marrow Transplant 2010.
58. Savani B.N., Pohlmann P.R., Jagasia M., et al. Does peritransplantation use of rituximab reduce the risk of EBV reactivation and PTLPD?. Blood 2009, 113:6263-6264.
59. Zhang M.M., Gopal A.K. Radioimmunotherapy-based conditioning regimens for stem cell transplantation. Semin Hematol 2008, 45:118-125.
60. Press O.W., Eary J.F., Appelbaum F.R., et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993, 329:1219-1224.
61. Gopal A.K., Gooley T.A., Maloney D.G., et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood 2003, 102:2351-2357.
62. Winter J.N., Inwards D., Spies S., et al. 90Y Ibritumomab tiuxetan (Zevalin(R); 90YZ) doses calculated to deliver up to 1500 cGy to critical organs may be safely combined with high-dose BEAM and autotransplant in NHL. ASH Annu Meet Abstr 2006, 108:330.
63. Vose J., Bierman P., Bociek G., et al. Radioimmunotherapy with 131-I tositumomab enhanced survival in good prognosis relapsed and high-risk diffuse large B-cell lymphoma (DLBCL) patients receiving high-dose chemotherapy and autologous stem cell transplantation. ASCO Meet Abstr 2007, 25:8013.
64. Gopal A.K., Pagel J.M., Rajendran J.G., et al. Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy. Biol Blood Marrow Transplant 2006, 12:697-702.
65. Khouri I.F., Saliba R.M., Hosing C., et al. Efficacy and safety of yttrium 90 (90Y) ibritumomab tiuxetan in autologous and nonmyeloablative stem cell transplantation (NST) for relapsed non-Hodgkin's lymphoma (NHL). ASH Annu. Meet. Abstr 2006, 108:315.